Comparative Pharmacology
Head-to-head clinical analysis: AMERSCAN MDP KIT versus AXUMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMERSCAN MDP KIT versus AXUMIN.
AMERSCAN MDP KIT vs AXUMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m medronate is a bone-seeking radiopharmaceutical that localizes in bone by chemisorption to hydroxyapatite crystals, particularly in areas of increased osteoblastic activity.
Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor; inhibits VEGFR-1, -2, -3, and PDGFR-β, Kit, and RET.
Intravenous administration of 10-20 mCi (370-740 MBq) for adult bone imaging. Administer 2-4 hours prior to imaging.
AXUMIN (florbetaben F 18) is a diagnostic radiopharmaceutical for PET imaging of beta-amyloid plaques. The recommended dose is 300 MBq (8.1 mCi) administered as a single intravenous bolus injection over 10-15 seconds, followed by a saline flush.
None Documented
None Documented
Terminal elimination half-life: approximately 6 hours (range 4-8 hours) for the diphosphonate component; reflects clearance from bone and renal elimination.
The terminal elimination half-life is approximately 2.7 hours (range 1.5-5.0 hours) in patients with normal renal function; this supports twice-daily dosing, but may be prolonged in renal impairment.
Renal: approximately 50-60% unchanged within 2-3 hours post-injection; biliary/fecal: negligible (<5%). The remainder is retained in bone (up to 40%) with slow release.
Renal elimination of unchanged drug accounts for approximately 60% of the administered dose; fecal excretion accounts for approximately 35% (mainly as unchanged drug); biliary excretion contributes to fecal elimination; less than 1% is excreted in urine as metabolites.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical